Prediabetes Market, By Drug Class, By Type, By Routes of Administration, By Age Group, By Gender, By Distribution Channel, By Geography

Description

Prediabetes Market is estimated to be valued at USD 345.2 Mn in 2025 and is expected to reach USD 709.9 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.85% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 345.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.85%	2032 Value Projection:	USD 709.9 Mn

The global prediabetes market has emerged as a significant concern in recent years, with an increasing number of individuals being diagnosed with this condition. Prediabetes is a state characterized by higher-than-normal blood sugar levels, but not high enough to be classified as type 2 diabetes. This condition is often considered a precursor to type 2 diabetes, and individuals with prediabetes are at a higher risk of developing diabetes, cardiovascular diseases, and other related complications. The rising prevalence of prediabetes worldwide has led to a growing demand for effective diagnosis, treatment, and management solutions, driving the growth of the global prediabetes market. This blog aims to provide an overview of the prediabetes market, its current trends, and future prospects.

Market Dynamics:

The global prediabetes market is driven by several factors, including the increasing prevalence of obesity and sedentary lifestyles, which are major risk factors for developing prediabetes. The growing awareness about the importance of early diagnosis and management of prediabetes is also contributing to the market growth. Governments and healthcare organizations worldwide are focusing on implementing screening programs and initiatives to identify individuals with prediabetes and provide them with appropriate interventions. However, the market growth may be restrained by factors such as the lack of awareness about prediabetes in certain regions, limited access to healthcare services, and the high cost of diagnosis and treatment. On the other hand, the market presents significant opportunities for players involved in the development of innovative diagnostic tools, personalized treatment approaches, and digital health solutions for prediabetes management. The increasing adoption of telemedicine and remote monitoring technologies is expected to further drive the market growth in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global prediabetes market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global prediabetes market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk, Johnson & Johnson, Merck & Co., Sanofi, Eli Lilly and Company, AstraZeneca, Bayer AG, Abbott Laboratories, Boehringer Ingelheim, GlaxoSmithKline, Amgen Inc., Takeda Pharmaceutical Company, Astellas Pharma, Pfizer Inc., and Novartis AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global prediabetes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prediabetes market

Market Segmentation

Drug Class Insights (Revenue, USD Mn, 2020 - 2032)
- Biguanides
- Metformin
- Phenformin
- Sulfonylureas
- Glipizide
- Glyburide
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Sitagliptin
- Saxagliptin
- Glucagon-Like Peptide-1 (GLP-1) Receptor
- Liraglutide
- Semaglutide
- Thiazolidinediones (TZDs)
- Pioglitazone
- Rosiglitazone
- Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
- Canagliflozin
- Dapagliflozin
- Insulin Therapy
- Insulin Glargine
- Insulin Lispro
- Combination Therapies
- Metformin + Sitagliptin
- Metformin + Glipizide
- Others
Type Insights (Revenue, USD Mn, 2020 - 2032)
- Prescription-only Drugs
- Over-the-Counter (OTC)
Routes of Administration Insights (Revenue, USD Mn, 2020 - 2032)
- Oral
- Subcutaneous
- Transdermal
- Inhalable/Intranasal
- Others
Age Group Insights (Revenue, USD Mn, 2020 - 2032)
- Children
- Adults
- Elderly
Gender Insights (Revenue, USD Mn, 2020 - 2032)
- Male
- Female
Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novo Nordisk
- Johnson & Johnson
- Merck & Co.
- Sanofi
- Eli Lilly and Company
- AstraZeneca
- Bayer AG
- Abbott Laboratories
- Boehringer Ingelheim
- GlaxoSmithKline
- Amgen Inc.
- Takeda Pharmaceutical Company
- Astellas Pharma
- Pfizer Inc.
- Novartis AG

Product Code: CMI8058

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Prediabetes Market, By Drug Class
- Global Prediabetes Market, By Type
- Global Prediabetes Market, By Routes of Administration
- Global Prediabetes Market, By Age Group
- Global Prediabetes Market, By Gender
- Global Prediabetes Market, By Distribution Channel
- Global Prediabetes Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Prediabetes Market, By Drug Class, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biguanides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  - Metformin
  - Phenformin
Sulfonylureas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  - Glipizide
  - Glyburide
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Sitagliptin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  - Liraglutide
  - Semaglutide
Thiazolidinediones (TZDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  - Pioglitazone
  - Rosiglitazone
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  - Canagliflozin
  - Dapagliflozin
Insulin Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  - Insulin Glargine
  - Insulin Lispro
Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  - Metformin + Sitagliptin
  - Metformin + Glipizide
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Prediabetes Market, By Type, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Prescription-only Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Over-the-Counter (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Prediabetes Market, By Routes of Administration, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Inhalable/Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Prediabetes Market, By Age Group, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Children
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Elderly
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Prediabetes Market, By Gender, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Prediabetes Market, By Distribution Channel, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Prediabetes Market, By Region, 2020 - 2032, Value (USD Mn)

Introduction
Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Routes of Administration, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Routes of Administration, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Routes of Administration, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Routes of Administration, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Routes of Administration, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Routes of Administration, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
South Africa
North Africa
Central Africa

11. Competitive Landscape

Novo Nordisk
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bayer AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Abbott Laboratories
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Boehringer Ingelheim
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GlaxoSmithKline
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Amgen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Takeda Pharmaceutical Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Astellas Pharma
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies

12. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

13. References and Research Methodology

References
Research Methodology
About us